NOBACCΟ occupies a leading position in its industry due to the fact that it provides only high quality e-liquids and vaping devices to its customers. For NOBACCO, product quality and safety is of paramount importance. For this reason, the company is constantly investing in the development of mechanisms that will further guarantee the production and distribution of products that adhere to the strictest of standards.
Nobacco Design Center is a specialized company with sole purpose to deliver the most innovative, user friendly, qualitative and contemporary vaping products.
Our workforce includes some of the greatest research and development engineers, extremely talented product designers, highly skilled sales representatives and powerful managers. Professionals, with 10 years experience in the vaping industry, Nobacco Design Center’s staff creates truly outstanding products that deliver the most enjoyable vaping experience.
Designed by us, designed for you.
Aquarius Project was established through the pioneer alliance of NOBACCO and LMBI (Laboratory of Molecular Biology and Immunology), Pharmaceutical Dept, Patras University.
NOBACCO’s partnership with the LMBI, Pharmaceutical Dept, Patras University is a pioneer initiative which puts the collaboration of the academic community with the private sector into practice, following the international trend to connect production with knowledge and innovation.
AQUARIUS PROJECT SA is the first company in Greece to specialize in the production of e-liquids for electronic cigarettes. All manufacturing procedures adhere to the strictest international standards.
The company’s driving force is the investment in the Greek research and innovation, such as the formation of the strategic alliance with the LMBI (Laboratory of Molecular Biology and Immunology), Pharmaceutical Dept, Patras University from 2014 to 2019.
Aquarius Project’s mission is to develop innovative products for millions of electronic cigarette users (vapers) in the world, abiding by the strictest international standards.
Its vision is to create a line of products that will gain the trust of vapers around the world and will add value to the production and entrepreneurship of Greece.
In 2017, NOBACCO started a new E-Liquid Quality Control and Assurance Program in collaboration with the School of Health Sciences of National and Kapodistrian University of Athens. Through this new partnership, NOBACCO ensures the integrity of all e-liquids and is able to reassure Greek consumers that its products are controlled over time and meet the strict standards adopted by the European Union.
The School of Health Sciences of National and Kapodistrian University of Athens applies innovative standards that exceed the requirements of the European Regulations and the competent authorities in order to ensure the consistent high quality of its products over time.
Within the framework of the new program, the Pharmacology Lab of the School of Health Sciences of National will carry out:
Random e-liquid sampling tests to quantify nicotine and analyze/classify the components of the solutions to verify the quality and consistency of their composition.
E-Liquid analyses to confirm the absence of substances such as diacetyl, acetylpropionyl, etc.
E-Liquid Analyses and Stability Controls to confirm and ensure the accuracy of e-liquid ingredients.
It is worth mentioning that NOBACCO is the only Greek company to cooperate with one of the most reputable university institutes in the country, School of Health Sciences of National and Kapodistrian University of Athens.
From April 2012 since the end of 2016, NOBACCO pioneers with its participation to the most complete and comprehensive program of control and certification of e-liquids run by the University of Thessaly.
Through its participation to the particular program, NOBACCO has managed to ensure the provision of even safer electronic cigarette products. This scientific Certification program, which is fully supported by the Hellenic Association of Electronic Cigarettes’ Entrepreneurs (HAECE), provides conclusive evidence that NOBACCO’s e-liquids are not harmful to humans and the environment. Additionally, e-liquids do not contain carcinogenic substances. More specifically, no nitrosamines and polycyclic aromatic hydrocarbons have ever been detected, in accordance with the European regulations, following the suggested lower detection limits. The implementation of such a rigorous certification program ensures the timeless provision of safe-to-use products.
NOBACCO’s e-liquids are inspected on a monthly basis from University, and have been certified according to the European Regulation no. 1272/2008 as to their composition and mixture of inhaled vapors that are released when using the solution in the e-cigarette.
Funding of research that aimed at the examination of the elasticity of blood vessels. The survey was conducted at the Onassis Cardiac Surgery Center and Dr. Farsalinos led the research team.
Financial support of ongoing clinical studies at the Greek hospital of EVAGELISMOS with professor of pharmaceutical chemistry of the University of Athens Andrea Papapetropoulo leading the research team.
Provision of equipment and financial support for a study that has been scheduled to take place at the 2nd Cardiology University Clinic of Atticus Hospital led by the head of department Mr. John Lekaki.
It is worth noting that NOBACCO is one of the five electronic cigarette companies across Europe that has been invited by the Commission to participate in shaping the regulatory framework for the European Tobacco Products Directive (2014/40/EU) that places all necessary safety regulations for electronic cigarette products.